Retigabine/Ezogabine, a KCNQ/KV7 channel opener: pharmacological and clinical data

Author： Orhan Gökce   Wuttke Thomas V   Nies Anne T   Schwab Matthias   Lerche Holger  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.12, 2012-08, pp. : 1807-1816

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacokinetics of Retigabine/Ezogabine

By  

Current Clinical Pharmacology, Vol. 8, Iss. 4, 2013-11 ,pp. : 319-331

Bentham Science Publishers

Access to resources Recommend Favorite

The Kv7 potassium channel activator retigabine decreases alcohol consumption in rats

By Knapp Clifford M.   O’Malley Matthew   Datta Subimal   Ciraulo Domenic A.  

The American Journal of Drug and Alcohol Abuse, Vol. 40, Iss. 3, 2014-05 ,pp. : 244-250

Informa Healthcare

Access to resources Recommend Favorite

The therapeutic potential of neuronal KV7 (KCNQ) channel modulators: an update

By Gribkoff Valentin K  

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 5, 2008-05 ,pp. : 565-581

Informa Healthcare

Access to resources Recommend Favorite

The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation

By Dost R.   Rostock A.   Rundfeldt C.  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 369, Iss. 4, 2004-04 ,pp. : 382-390

Springer Publishing Company

Access to resources Recommend Favorite

Retigabine (Ezogabine): In Partial-Onset Seizures in Adults with Epilepsy

By Deeks Emma D.  

CNS Drugs, Vol. 25, Iss. 10, 2011-10 ,pp. : 887-900

Adis International

Access to resources Recommend Favorite